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ABSTRACT
Background There are limited data on the burden of
cardiovascular comorbidities in people with
bronchiectasis. Our cross-sectional study estimates the
burden of pre-existing diagnoses of coronary heart
disease (CHD) and stroke in people with bronchiectasis
compared with the general population. The historical
cohort study investigates if individuals with
bronchiectasis are at increased risk of incident CHD and
stroke events.
Methods We used primary care electronic records from
the Clinical Practice Research Datalink. The cross-
sectional study used logistic regression to quantify the
association between bronchiectasis and recorded
diagnoses of CHD or stroke. Cox regression was used to
investigate if people with bronchiectasis experienced
increased incident CHD and strokes compared with the
general population, adjusting for age, sex, smoking habit
and other risk factors for cardiovascular disease.
Results Pre-existing diagnoses of CHD (OR 1.33, 95%
CI 1.25 to 1.41) and stroke (OR 1.92, 95% CI 1.85 to
2.01) were higher in people with bronchiectasis
compared with those without bronchiectasis, after
adjusting for age, sex, smoking and risk factors for
cardiovascular disease. The rate of ﬁrst CHD and stroke
were also higher in people with bronchiectasis (HR for
CHD 1.44 (95% CI 1.27 to 1.63) and HR for stroke
1.71 (95% CI 1.54 to 1.90)).
Conclusion The risk of CHD and stroke are higher
among people with bronchiectasis compared with the
general population. An increased awareness of these
cardiovascular comorbidities in this population is needed
to provide a more integrated approach to the care of
these patients.
INTRODUCTION
Bronchiectasis is a chronic lung disease charac-
terised by repeated episodes of infection and
chronic inﬂammation.1 Current best estimates
suggest that almost 20 000 new cases are diagnosed
annually, over 300 000 people in the UK have a
diagnosis of bronchiectasis at present,2 and just
under 1000 people die from bronchiectasis each
year.3
Individuals with other chronic respiratory dis-
eases have been shown to be at increased risk of
cardiovascular disease.4–6 While these data could
be extrapolated to include people with bronchiec-
tasis as they share common risk factors of cardio-
vascular disease, such as hypoxia and systemic
inﬂammation, there are limited data on the extent
to which cardiovascular comorbidities exist in bron-
chiectasis. Some studies have suggested a high
prevalence of cardiovascular disease7 and cardiac
dysfunction8 in people with bronchiectasis and
more recently, a case-control study demonstrated
that people with bronchiectasis had increased arter-
ial stiffness compared with matched controls.9
We used UK primary care data to quantify the
burden of cardiovascular comorbidities among
people with bronchiectasis compared with the
general population. We also determined if indivi-
duals with bronchiectasis are at higher risk of ﬁrst-
time cardiovascular events compared with those
without bronchiectasis.
METHODS
Data source
The Clinical Practice Research Datalink (CPRD) is
an anonymised primary care database from 625
general practices throughout the UK10 (http://www.
cprd.com). Information is recorded as part of
routine care, from face-to-face consultations and
Key messages
What is the key question?
▸ Do people with bronchiectasis have more
cardiovascular comorbidities compared with the
general population and are they at increased
risk of incident cardiovascular events?
What is the bottom line?
▸ People with bronchiectasis are at increased risk
of cardiovascular disease, which does not
appear to be attributable to smoking, other
established cardiovascular risk factors or
comorbidities associated with the aetiology of
bronchiectasis, suggesting that bronchiectasis
may be an independent risk factor for
cardiovascular disease.
Why read on?
▸ This is the largest population-based study to
quantify the association between bronchiectasis
and cardiovascular disease, which needs to be
highlighted to physicians in order to provide a
holistic approach to the care of these patients
and health service pathways can be integrated
to include management of these comorbidities.
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following communication from secondary care. Data used for
research need to meet a series of quality checks and have been
deemed ‘up to standard’ for research use by CPRD.
Approval had been obtained from the Independent Scientiﬁc
Advisory Committee, which oversees research involving CPRD
data (protocol ref: 13_03R; available on request) and the
London School of Hygiene and Tropical Medicine Ethics
Committee (LSHTM MSc ethics ref: 012-137).
Study population
Our study population consisted of all individuals aged over
18 years, alive and contributing to CPRD at any point between
1 January 2004 and 31 December 2011 with at least 1 year of
records that were ‘up to standard’ prior to entry into the study.
Previously published pre-speciﬁed Read code lists developed
by a clinical epidemiologist, who is also a consultant respiratory
physician, were used to identify people with bronchiectasis.2
Individuals were deﬁned as having bronchiectasis if they were
over 18 years, had a diagnosis recorded prior to our index date (a
randomly chosen date, which was 25 April 2006) and did not
have a diagnosis of cystic ﬁbrosis (CF). We also extracted infor-
mation on demographic factors, comorbid illnesses associated
with the aetiology of bronchiectasis and cardiovascular risk
factors (hypertension, diabetes mellitus, hyperlipidaemia,
smoking habit, family history of cardiovascular disease). Smoking
status was deﬁned using information recorded closest to the
index date. Individuals without a record of smoking habit were
grouped into a stratum for missing smoking information. Each
cardiovascular risk factor was classiﬁed as present if the ﬁrst
record for the condition was prior to the index date.
Comorbidities associated with the aetiology of bronchiectasis
were considered present if the ﬁrst record of the comorbid illness
was either prior to the index date or during the study period.
Deﬁnition of outcomes
Medical records were searched for diagnoses of coronary heart
disease (CHD) and/or stroke. The validity of recorded diagnoses
has previously been established.11–13 CHD was a composite
outcome of having at least one recorded diagnosis of angina
(including unstable angina), myocardial infarction (MI) or cor-
onary artery bypass graft (CABG). Our deﬁnition of stroke
included ischaemic or haemorrhagic stroke, transient ischaemic
attack and subarachnoid haemorrhage.
Analysis strategy
We conducted a cross-sectional study to determine if the diagno-
ses of CHD and stroke were higher in people with bronchiec-
tasis, followed by a cohort study to investigate whether those
with bronchiectasis were at increased risk of incident CHD and
stroke events. We used the same index date for both analyses,
which was 25 April 2006.
Cross-sectional analysis
The primary outcomes were existing diagnoses of CHD and
stroke prior to the index date.
Logistic regression was used to estimate the association
between bronchiectasis and CHD and stroke as separate out-
comes, adjusting for age, sex and smoking habit as a priori con-
founders. We repeated the analyses, also adjusting for
cardiovascular risk factors to explore to what extent these
potentially explained the association between bronchiectasis and
cardiovascular disease. Multiplicative interaction terms were
applied to investigate effect measure modiﬁcation by age or sex.
The interaction term was retained in the model if provided a
better ﬁt for the data, using likelihood ratio testing. These ana-
lyses were repeated for the individual CHD outcomes, in turn.
Historical cohort analysis
First-time diagnoses of CHD and stroke after the index date
were considered as incident events in these analyses. We
excluded individuals with a previous record of CHD or stroke
prior to the index date, as the risk of a second event is likely to
differ from the ﬁrst. All individuals were assigned a start date
(which was the index date; 25 April 2006) and a stop date
which was the earliest of date of outcome, date of death, date of
transfer to another practice or 31 December 2011. Crude rates
of CHD and stroke were calculated and Cox regression was
used to determine if people with bronchiectasis have an
increased rate of ﬁrst CHD diagnosis or stroke events than those
without bronchiectasis. A similar approach was used to assess
confounding and effect measure modiﬁcation, using baseline
values for cardiovascular risk factors recorded prior to the index
date. Nelson-Aalen methods were used to calculate cumulative
incidence of CHD and stroke. The proportional hazards
assumption was conﬁrmed using graphical methods.
Sensitivity analyses
We performed sensitivity analyses to explore the impact of
comorbidities associated with the aetiology of bronchiectasis and
effect of missing smoking data on the association between bron-
chiectasis and outcomes. The analyses were repeated excluding
individuals with comorbidities associated with the aetiology of
bronchiectasis (see online supplementary appendix 1). As our
main analyses included individuals without recorded information
on smoking habit in a stratum for missing information, the
smoking sensitivity analyses were repeated after restricting our
dataset to (1) only current smokers, (2) only individuals who
never smoked and (3) excluding anyone with missing smoking
information. Finally, since CHD and stroke events are fatal and
possibly competing risks, we repeated the main historical cohort
analyses with a competing risk adjustment.
Likelihood ratio tests were used for all hypothesis testing. All
statistical analyses were conducted using Stata (V.12; Texas,
USA).
Power calculation
The prevalence of CHD and stroke in the UK general population
is approximately 3.2% and 1.4%, respectively. With 10 942
people with bronchiectasis and 3.8 million people without bron-
chiectasis, this study had in excess of 90% power to detect an
OR of ≥1.5. For the survival analysis, there are approximately
103 000 MIs and 152 000 strokes each year in the UK. As CPRD
covers approximately 8% of the UK population, 6180 MIs and
9120 strokes would be expected to be recorded in CPRD. A total
of 66 CHD or stroke events would be required to detect a HR of
≥1.5, with a power of 80% and a signiﬁcance level of 0.05.
RESULTS
Study population
A total of 3 895 710 adults alive and contributing to CPRD on
the 25 April 2006 were included in our study population. There
were slightly more women (50.8%) and the median age at the
index date was 47 years (IQR: 34–62). A total of 10 942 people
(0.3%) had a record of bronchiectasis prior to the index date;
the majority were female (60.4%) and the median age at diag-
nosis was 56.5 years (IQR 41.5–67.6). About 33.6% of indivi-
duals with bronchiectasis were current smokers (see table 1).
About 63% of people with bronchiectasis had one or more
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comorbidities associated with the aetiology of the disease (see
online supplementary appendix 1). The prevalence of risk
factors for CHD or stroke was higher in people with bronchiec-
tasis (see table 1).
Cross-sectional study
In total, 2417 individuals with bronchiectasis had a diagnosis of
CHD or stroke; 12.9% of individuals had a history of CHD
and 9.2% had a history of stroke prior to the index date (see
table 2). Median time between recording of the CHD event and
the index date was 8.3 and 7.7 years in people with and without
bronchiectasis, while median time between record of stroke and
the index date was 4.1 years in individuals with bronchiectasis
and 5.3 years in those without bronchiectasis. After adjusting
for age, sex, smoking, hypertension, hyperlipidaemia, diabetes
mellitus and family history of cardiovascular disease, the odds
of CHD was 33% higher in people with bronchiectasis com-
pared with those without bronchiectasis (OR 1.33, 95% CI
1.25 to 1.41; p<0.001). Recorded diagnosis of CHD in indivi-
duals with bronchiectasis varied with age (p<0.001) and was
highest in those aged ≤45 years (see table 2). We found no evi-
dence of effect measure modiﬁcation by gender (p=0.342).
We found an almost twofold increase in recorded diagnoses
of stroke in people with bronchiectasis after adjusting for the a
priori confounders and cardiovascular risk factors (OR 1.93,
95% CI 1.85 to 2.01; p=0.007) (see table 2). There was no evi-
dence of statistical interaction by age (p=0.171) or sex
(p=0.696). All individual CHD outcomes were also more
common in people with bronchiectasis compared with the
general population (see table 3).
Historical cohort study
After excluding individuals with a previous record of CHD or
stroke prior to the index date, our cohort consisted of 8622
individuals with bronchiectasis and 3 637 924 individuals
without bronchiectasis. The historical cohort was followed up
for a median of 5.6 years (IQR: 5.1–5.8), during which there
were 40 110 CHD events. The crude rates of ﬁrst CHD event
in people with and without bronchiectasis were 6.6 per 1000
person-years (95% CI 5.9 to 7.5) and 2.2 per 1000 person-years
(95% CI 2.1 to 2.3), respectively (see ﬁgure 1). The rate of ﬁrst
CHD event was 42% higher in people with bronchiectasis com-
pared with those without bronchiectasis, after controlling for
the effects of age, sex and smoking habit (HR 1.42, 95% CI
1.25 to 1.60; p<0.001). Adjusting for diabetes, hypertension,
hyperlipidaemia and family history of cardiovascular disease in
addition to the a priori confounders had minimal impact on the
rate of CHD (HR 1.44, 95% CI 1.27 to 1.63). There was
minimal evidence of effect measure modiﬁcation by age
(p=0.181) or sex (p=0.233).
A total of 41 713 strokes occurred during follow-up, which
equated to a crude ﬁrst stroke rate of 9.4 per 1000 person-years
(95% CI 8.5 to 10.4) and 2.4 per 1000 person-years (95% CI
2.2 to 2.4) in people with and without bronchiectasis, respect-
ively (see ﬁgure 2). After adjusting for age, sex and smoking
habit, the rate of ﬁrst stroke was 69% higher in those with bron-
chiectasis compared with individuals without bronchiectasis
(HR 1.69, 95% CI 1.52 to 1.87; p<0.001). Additional adjust-
ment with cardiovascular risk factors had little effect on the rate
of stroke (HR 1.71, 95% CI 1.54 to 1.90; p<0.001). There was
limited evidence that the effect of bronchiectasis on acute stroke
varied by age (p=0.217) or gender (p=0.105). The data were
consistent with the proportional hazards assumption.
Sensitivity analysis
The sensitivity analyses had marginal change on the ORs and
HRs for CHD and stroke (see table 4).
DISCUSSION
This population-based study of almost 4 million people has
three main ﬁndings. First, we found that individuals with bron-
chiectasis had higher pre-existing comorbidities of CHD and
Table 1 Baseline characteristics of people with bronchiectasis and
those without bronchiectasis
Characteristic
No. of people
without
bronchiectasis (%)
(n=3 884 770)
No. of people
with
bronchiectasis (%)
(n=10 942)
Sex
Male 1 910 218 (49.2) 4339 (39.7)
Female 1 974 552 (50.8) 6603 (60.4)
Age category (years)
19–45 1 777 981 (45.8) 925 (8.5)
45–54 675 485 (17.4) 1143 (10.5)
55–64 613 095 (15.8) 2651 (24.2)
65–74 415 096 (10.7) 3140 (28.7)
≥75 403 113 (10.3) 3083 (28.2)
Smoking status
Never-smoker 1 640 051 (42.2) 4119 (37.6)
Ex-smoker 649 519 (16.7) 3151 (28.8)
Current smoker 1 397 503 (36.0) 3672 (33.6)
Missing data 197 697 (5.1) 0
Hypertension 691 520 (17.8) 3771 (34.5)
Hyperlipidaemia 250 749 (6.5) 1296 (11.8)
Diabetes 185 964 (4.8) 951 (8.7)
Family history of
cardiovascular disease
787 871 (20.3) 2981 (27.2)
Table 2 Adjusted ORs for the association between coronary heart disease or stroke and bronchiectasis
Outcome
No. of people
without
bronchiectasis (%)
(n=3 884 768)
No. of people with
bronchiectasis (%)
(n=10 942)
Adjusted OR
(95% CI)*
Adjusted OR
(95% CI)†
Stratum-specific adjusted OR (95% CI)
Age category (years)†
≤45 46–54 55–64 65–74 ≥75
Coronary heart
disease
178 944 (4.6) 1409 (12.9) 1.24
(1.16 to 1.31)
1.33
(1.25 to 1.41)
4.43
(2.20 to 8.93)
1.99
(1.44 to 2.76)
1.70
(1.47 to 1.96)
1.35
(1.21 to 1.50)
1.15
(1.05 to 1.26)
Stroke 139 543 (3.6) 1008 (9.2) 1.88
(1.80 to 1.96)
1.92
(1.85 to 2.01)
– – – – –
*Adjusted for age, gender and smoking.
†Adjusted for age, gender, smoking, diabetes, hypertension, hyperlipidaemia and family history of cardiovascular disease.
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stroke compared with the general population. Second, there
were increased recorded diagnoses of MI and CABG, suggesting
that people with bronchiectasis are also likely to have more
severe disease requiring intervention. Third, our historical
cohort study found that people with bronchiectasis had an
increased rate of ﬁrst CHD and stroke events compared with
those without bronchiectasis. Our estimates suggest that one in
ﬁve individuals with bronchiectasis will have an existing diagno-
sis of either CHD or stroke and approximately 2500 patients
with bronchiectasis will suffer from a ﬁrst cardiovascular event
each year. These individuals are at much higher risk of future
vascular events and premature mortality. In absolute terms, our
ﬁndings suggest that if a cohort of 100 people with bronchiec-
tasis were followed up for 5 years, they would have three CHD
events and ﬁve strokes, whereas 100 people without bronchiec-
tasis would have one CHD event and one stroke.
There are sparse data on the prevalence of cardiovascular
disease or risk factors among people with bronchiectasis. A
study of 98 patients with bronchiectasis suggested that patients
with bronchiectasis have a high prevalence of cardiovascular-
related illnesses: 19.4% had cardiovascular comorbidities,
21.1% had hypertension and 5.1% had diabetes.7 A more
recent case-control study of 20 cases of bronchiectasis and 20
controls matched for age, sex and smoking status found that
cases with bronchiectasis had higher aortic pulse wave velocity,
an independent predictor of cardiovascular risk, compared with
controls.9 We have previously shown that age-speciﬁc all-cause
mortality rates were higher in people with bronchiectasis com-
pared with the general population, including those under the
age of 50.14 Although the underlying reason for increased mor-
tality in individuals with bronchiectasis remains unclear, the
ﬁndings of this study raise the possibility that it could be partly
driven by increased cardiovascular disease.
A large proportion of individuals with bronchiectasis in our
dataset had comorbidities associated with the aetiology of bron-
chiectasis, some of which have been associated with increased
risk of cardiovascular disease. Our sensitivity analyses only
including people with idiopathic or post-infectious bronchiec-
tasis suggest that the increased risk of CHD and stroke is not
driven by these comorbidities. We were not able to distinguish
between people with idiopathic and post-infectious bronchiec-
tasis, as only a small proportion of our bronchiectasis cohort
had speciﬁc Read codes for post-infectious bronchiectasis.
While it is possible that some of our ﬁndings of increased risk
of CHD could be due to ascertainment bias, our study also
demonstrated increased incidence and prevalence of stroke,
which is diagnosed after acute symptoms and conﬁrmation by
CT, suggesting that our ﬁndings are unlikely to be due to ascer-
tainment bias alone.
The association between CHD and stroke with bronchiectasis
may be due a number of reasons; it could be because the dis-
eases share similar risk factors. Studies have suggested that indi-
viduals with bronchiectasis have increased systemic
inﬂammation,15–17 which is a risk factor for the development of
atherosclerosis.18 Acute infections which occur more frequently
in people with bronchiectasis may also result in a transient
increase in the risk of vascular events.19 Although possible that
the increased risk in CHD and stroke seen in our study is driven
by smoking or by comorbidities associated with bronchiectasis,
our sensitivity analyses (1) excluding those with comorbid ill-
nesses associated with bronchiectasis and (2) restricted to
only never-smokers showed marginal change to our results.
Table 3 Adjusted ORs for the association between bronchiectasis and individual coronary heart disease outcomes
Outcome
No. of people without
bronchiectasis (%)
(n=3 884 768)
No. of people with
bronchiectasis (%)
(n=10 942) Adjusted OR (95% CI)* Adjusted OR (95% CI)† p Value‡
Angina 116 697 (3.0) 936 (8.6) 1.25 (1.16 to 1.34) 1.33 (1.24 to 1.43) <0.001
Coronary artery bypass graft 8657 (0.2) 45 (0.4) 1.84 (1.63 to 2.13) 1.87 (1.65 to 2.17) <0.001
Myocardial infarction 78 411 (2.0) 518 (4.7) 1.08 (0.98 to 1.18) 1.11 (1.01 to 1.22) 0.012
*Adjusted for age, gender and smoking.
†Adjusted for age, gender, smoking, diabetes, hypertension, hyperlipidaemia and family history of cardiovascular disease.
‡p Value from likelihood ratio test.
Figure 1 Nelson-Aalen cumulative incidence of coronary heart
disease in people with bronchiectasis and those without bronchiectasis
is shown.
Figure 2 Nelson-Aalen cumulative incidence of stroke in people with
bronchiectasis and those without bronchiectasis is shown.
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While it is also possible that reverse causality may be present,
our cohort study only included people without prior cardiovas-
cular events. There is some evidence that chronic multisystem
inﬂammatory disorders are associated with increased risk of car-
diovascular disease.20 Our ﬁndings of an increased risk of CHD
and stroke in people with bronchiectasis raises the possibility
that systemic inﬂammation itself is a direct risk factor for vascu-
lar disease.
One of the strengths of our study is the large study popula-
tion, which enabled us to quantify the burden of cardiovascular
comorbidities as well as individual CHD events (eg, angina,
MI), explore confounding or potential mediation by cardiovas-
cular risk factors and investigate effect measure modiﬁcation by
age and gender. The prevalence of CHD and stroke in our
general population is similar to that in national data,21 reassur-
ing us of the validity of these diagnoses in our study population,
despite the possibility of misclassiﬁcation. Furthermore, studies
have also demonstrated the validity of medical diagnoses22 23
and prescribing records in CPRD.24 A further strength is the use
of prospectively collected data from electronic medical records,
which minimises the possibility of misclassiﬁcation due to recall
or observer bias. Although general practices are self-selecting
with regard to contributing to CPRD, the population of patients
within CPRD is broadly representative of the UK population.10
A potential limitation of our study is validity of diagnosis of
bronchiectasis. We used a small number of speciﬁc previously
published Read codes to identify people with bronchiectasis,2
only included those aged over 18 years when diagnosed and
excluded individuals with a diagnosis of CF to improve the sen-
sitivity and speciﬁcity of our bronchiectasis cohort. We were
unable to validate the diagnosis of bronchiectasis in our dataset
as we did not have access to radiological information. Hence it
is not possible to conﬁrm that the diagnoses of bronchiectasis in
these data were made according to current guidelines. However,
bronchiectasis is usually diagnosed in secondary care after inves-
tigation with CT scans25 26; hence it seems unlikely for a diag-
nosis of bronchiectasis to be recorded in primary care without
conﬁrmation from secondary care. The prevalence of bronchiec-
tasis in our study population is comparable with other studies
and the demographic features are consistent with the UK popu-
lation of patients with bronchiectasis,26 27 providing further
reassurance that the diagnosis of bronchiectasis in our dataset is
valid. It also needs to be acknowledged that our bronchiectasis
cohort is likely to represent a heterogeneous group of patients
with a diagnosis of bronchiectasis in their medical records. We
did not have information on disease severity or number of hos-
pitalisations for exacerbations and it is possible that the risk of
cardiovascular disease may vary with severity of disease.
Another potential limitation is missing smoking data in people
without bronchiectasis. However, our sensitivity analyses
suggest that impact of missing smoking information on the asso-
ciation between bronchiectasis and outcomes is marginal. We
assumed that risk factors for CHD and stroke were present if
coded and absent if not. However, it is possible that missing
data for risk factors were misclassiﬁed as absent. Although this
may result in some residual confounding, it does not fully
explain the association between bronchiectasis and cardiovascu-
lar disease. A further possible limitation is that most CHD and
stroke events are likely to be diagnosed in secondary care and
there may be a delay in recording these events in primary care,
particularly at the end of our study period. This may result in
an underestimation of the association between bronchiectasis
and cardiovascular disease.
Our study suggests that people with bronchiectasis have
higher existing cardiovascular comorbidities and a marked
increase risk of CHD and strokes. Further research to better
understand the biological mechanism behind this association is
warranted. With increasing specialisation of secondary care ser-
vices, clinical awareness of the extent to which cardiovascular
comorbidities exist in people with bronchiectasis needs to be
raised so that a holistic approach towards patient management
can be taken and incorporated into health service models in
order to improve patient care.
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